We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+102%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$346M
AUM Growth
+$140M
Cap. Flow
+$48.5M
Cap. Flow %
14.01%
Top 10 Hldgs %
48.64%
Holding
51
New
19
Increased
12
Reduced
13
Closed
5

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$15.9M
2
KURA icon
Kura Oncology
KURA
+$9.73M
3
LRMR icon
Larimar Therapeutics
LRMR
+$8.24M
4
IMVT icon
Immunovant
IMVT
+$7.5M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$7.32M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$16.8M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.2M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$8.12M
4
ARVN icon
Arvinas
ARVN
+$6.67M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 91.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
26
Altimmune
ALT
$583M
$5.76M 1.66%
+537,500
New +$2.95M
VIR icon
27
Vir Biotechnology
VIR
$1.5B
$5.2M 1.5%
+127,000
New +$4.26M
VSTM icon
28
Verastem
VSTM
$500M
$4.56M 1.32%
220,833
-89,245
-29% -$2.36M
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.32M 1.25%
170,000
-86,500
-34% -$1.86M
ARVN icon
30
Arvinas
ARVN
$520M
$4.13M 1.19%
123,000
-157,120
-56% -$6.67M
ALDX icon
31
Aldeyra Therapeutics
ALDX
$92.3M
$3.71M 1.07%
+890,000
New +$3.25M
AGEN
32
Agenus
AGEN
$346M
$3.67M 1.06%
+47,511
New +$2.85M
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.7B
$3.57M 1.03%
+240,744
New +$3.67M
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.51M 1.01%
687,500
+548,500
+395% +$2.29M
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$3.32M 0.96%
+117,500
New +$3.39M
EIGR
36
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.81M 0.81%
+9,750
New +$2.87M
QURE icon
37
uniQure
QURE
$3.06B
$2.7M 0.78%
60,000
+7,000
+13% +$413K
ARWR icon
38
Arrowhead Research
ARWR
$12.1B
$2.59M 0.75%
60,000
-49,700
-45% -$1.75M
RETA
39
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.39M 0.69%
15,300
-8,200
-35% -$1.25M
FUSN
40
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.36M 0.68%
+135,000
New +$2.35M
GBIO
41
DELISTED
Generation Bio
GBIO
$2.1M 0.61%
+10,000
New +$2.23M
CRDF icon
42
Cardiff Oncology
CRDF
$72.7M
$2.04M 0.59%
+407,500
New +$834K
SURF
43
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.48M 0.43%
+225,000
New +$812K
WVE icon
44
Wave Life Sciences
WVE
$1.13B
$1.12M 0.32%
+107,500
New +$1.01M
STSA
45
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$1.01M 0.29%
+35,000
New +$810K
AKUS
46
DELISTED
Akouos Inc
AKUS
$500K 0.14%
+22,200
New +$495K
ABUS icon
47
Arbutus Biopharma
ABUS
$861M
– –
-269,907
Closed -$273K
AUPH icon
48
Aurinia Pharmaceuticals
AUPH
$1.87B
– –
-770,000
Closed -$11.2M
MRNS
49
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-259,500
Closed -$2.11M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-39,000
Closed -$1.99M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Acuta Capital Partners held 51 positions worth $346M, up 68% from $206M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Acuta Capital Partners deployed $48.5M of net new capital in Q2 2020, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 545,000 shares worth $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $16.8M trimmed.

  • Acuta Capital Partners's largest Q2 2020 buy was Immunomedics Inc: 545,000 shares worth $19.3M.
  • Acuta Capital Partners added most to Kura Oncology in Q2 2020, an estimated $9.73M increase.
  • Acuta Capital Partners's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $16.8M.
  • Acuta Capital Partners fully exited Aurinia Pharmaceuticals in Q2 2020, selling an estimated $11.2M.
  • Acuta Capital Partners's ten largest holdings make up 49% of its $346M portfolio in Q2 2020.
  • Acuta Capital Partners opened 19 new positions and closed 5 in Q2 2020.
  • Acuta Capital Partners's portfolio value rose 68% quarter-over-quarter to $346M.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.